Viimased lisandused - Paraneoplastic / Auto-immune Chorioretinopathy
|
Auto-immune retinopathyvaatamisi: 3273 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2673 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2873 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2573 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2273 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2773 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2773 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2673 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2573 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2773 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2473 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Auto-immune retinopathyvaatamisi: 2973 year old man with mild vision loss and history of melanoma now with CLLjuuli 20, 2026
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 37067 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 34367 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 40167 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33367 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 34567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 34567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33467 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 31167 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 31967 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32167 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 37567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 36667 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 35167 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33667 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33267 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 34467 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32367 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32867 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 35267 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 31167 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 30867 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32867 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33867 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 35967 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32667 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33067 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 31367 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32367 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 29567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33267 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33767 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 32367 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 33567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 36567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 35767 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 36367 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 31967 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 35567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 35567 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 31767 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)vaatamisi: 37267 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.  A retinal evaluation showed subretinal fluid and vision loss.  The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions. Â
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.jaan 06, 2022
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 54858 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 51658 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 49158 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 49358 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 48158 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 47758 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 45958 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 42458 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 48658 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 48858 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 46058 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 52058 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 47358 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 52358 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 47558 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 48458 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 48558 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 43558 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 43458 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 46158 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 44558 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 54058 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 59558 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 48358 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Multifocal Vitelliform Macular Dystrophyvaatamisi: 64758 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MDmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 46591 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 46791 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 50591 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 46391 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 51291 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 55091 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 49891 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 47491 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 47091 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 48191 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 48391 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 51191 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 57391 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 52391 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 54591 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 46991 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 53891 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 44391 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 46891 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 49991 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
Autoimmune Retinopathyvaatamisi: 50391 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OSmai 06, 2019
|
|
|
|
